Compare Stocks

→ He Is Giving Away Bitcoin (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADDXF Addex Therapeutics	$0.99	$0.99	$0.99 ▼ $0.99	N/A	0.25	N/A	N/A
ADIL Adial Pharmaceuticals	$1.70 -10.5%	$1.67	$0.77 ▼ $14.00	$6.89M	1.49	5.19 million shs	439,648 shs
AZRX AzurRx BioPharma	$3.12 +7.2%	$4.04	$3.36 ▼ $26.30	$29.10M	1.51	628,703 shs	150,985 shs
CNSP CNS Pharmaceuticals	$0.21 +5.0%	$0.31	$0.19 ▼ $2.98	$2.23M	2.67	369,723 shs	142,355 shs
TLGT Teligent		$0.03	$0.17 ▼ $1.60	N/A	N/A	N/A	6,460 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADDXF Addex Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
ADIL Adial Pharmaceuticals	-1.55%	-27.20%	+11.76%	+49.89%	-76.62%
AZRX AzurRx BioPharma	+11.92%	-11.01%	-34.16%	-19.17%	+5.05%
CNSP CNS Pharmaceuticals	-1.44%	-16.83%	-47.33%	-64.57%	-89.47%
TLGT Teligent	0.00%	0.00%	0.00%	0.00%	0.00%

Thousands of investors use this no cost solution | Do you? (Ad)

In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.

Simply tap here now to subscribe and start getting "Insider Financial Advantage"

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADIL Adial Pharmaceuticals	0.7732 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.8	0.6
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$2.46 per share	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	($0.71) per share	N/A
TLGT Teligent	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADDXF Addex Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ADIL Adial Pharmaceuticals	-$5.12M	-$5.72	N/A	N/A	N/A	N/A	-250.52%	-183.24%	5/10/2024 (Estimated)
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
CNSP CNS Pharmaceuticals	-$18.85M	-$5.66	N/A	∞	N/A	N/A	-603.40%	-421.35%	5/20/2024 (Estimated)
TLGT Teligent	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADDXF Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
CNSP CNS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TLGT Teligent	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADDXF Addex Therapeutics	N/A	N/A	N/A
ADIL Adial Pharmaceuticals	N/A	4.90	4.90
AZRX AzurRx BioPharma	N/A	1.33	1.33
CNSP CNS Pharmaceuticals	N/A	0.26	0.26
TLGT Teligent	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ADDXF Addex Therapeutics	N/A
ADIL Adial Pharmaceuticals	16.41%
AZRX AzurRx BioPharma	6.27%
CNSP CNS Pharmaceuticals	14.02%
TLGT Teligent	N/A

Insider Ownership

Company	Insider Ownership
ADDXF Addex Therapeutics	N/A
ADIL Adial Pharmaceuticals	14.47%
AZRX AzurRx BioPharma	7.30%
CNSP CNS Pharmaceuticals	3.88%
TLGT Teligent	0.17%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADDXF Addex Therapeutics	26	N/A	N/A	Not Optionable
ADIL Adial Pharmaceuticals	16	4.05 million	3.47 million	No Data
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
CNSP CNS Pharmaceuticals	3	10.64 million	10.22 million	Not Optionable
TLGT Teligent	2,357	N/A	N/A	Optionable

ADIL, TLGT, ADDXF, CNSP, and AZRX Headlines

Source	Headline
	Topical pain reliever recalled for problem that can cause ‘severe morbidity, even death’ charlotteobserver.com - June 7 at 10:18 AM
	β1 Adrenoceptor Agonists Market 2023 Newest Industry Data ... - StreetBuzz news.google.com - May 13 at 1:32 AM
	Lidocaine Ointment Market Upcoming Trends, Size, Key Players ... - Taiwan News news.google.com - May 13 at 1:32 AM
	Global Mobile Value-Added Services (VAS) Industry Market Report ... - Industry Today news.google.com - May 11 at 4:41 AM
	Global Clindamycin Phosphate Topical Market Analysis, Share ... - The Northwestern Examiner news.google.com - May 8 at 10:54 AM
	Dry Skin Treatment Market Products, Share, Types, Applications, Growth, Insights and Forecasts Report to 2028 - openPR news.google.com - May 8 at 5:54 AM
	Mobile Value-Added Services (VAS) Market Size, Growth ... - Digital Journal news.google.com - May 8 at 5:54 AM
	Mobile Value-Added Services (VAS) Market 2023 Global Insights ... - The Northwestern Examiner news.google.com - May 5 at 9:12 AM
	Epinephrine For Allergy Treatment Market Dynamic Growth Factors ... - Digital Journal news.google.com - May 3 at 7:08 AM
	Erythromycin Market with Focus on Growth Analysis, Production ... - Digital Journal news.google.com - May 2 at 8:42 AM
	From 2023 to 2031 Mobile Value-Added Services (VAS) Market ... - Digital Journal news.google.com - April 29 at 8:17 AM
	Tremendous Growth Of Drugs To Relieve Paraneoplastic Pemphigus Market (2023-2030 )Industry Insights, SWOT Anal - openPR news.google.com - April 28 at 10:17 PM
	Drugs to Relieve Paraneoplastic Pemphigus Market 2023 Provides Top Companies Data, Top Key Players, Types and - openPR news.google.com - April 26 at 1:32 PM
	Topical Drug Delivery Market Production Capacity Estimates, Industry Size, Current Trend, Competition, Growth, - openPR news.google.com - April 26 at 8:32 AM
	Triamcinolone Market \| Driving Factors, Industry Analysis ... - Taiwan News news.google.com - April 24 at 4:23 PM
	IDT Corp. Cl B wsj.com - April 23 at 2:59 AM
	Mobile Value-Added Services (VAS) Markets edge up Strategic ... - Digital Journal news.google.com - April 17 at 2:17 PM
	Hikma Names Injectables Chief Mishlawi As CEO - Generics Bulletin news.google.com - April 12 at 1:13 PM
	Mobile Value-Added Services (VAS) Market is Anticipated to Shown ... - Digital Journal news.google.com - April 10 at 1:16 PM
	Everstream Names Ken Fitzpatrick as President and Chief Executive ... - Joplin Globe news.google.com - April 6 at 1:58 PM
	Lidocaine Ointment Market Growth Till, 2023-2030: Coherent Market ... - Digital Journal news.google.com - March 29 at 7:08 AM
	Mobile Value-Added Services (VAS) Maket Is Set to Fly High in ... - Digital Journal news.google.com - March 29 at 2:07 AM
	Gonorrhea Treatment Market Size 2023 - Current Sales Analysis, Upcoming Trends, Opportunities, Development His - openPR news.google.com - March 28 at 10:26 AM
	Bankruptcy Standing: An Introduction to a Multitude \| Reed Smith ... - JD Supra news.google.com - March 25 at 8:59 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Foot Locker Builds Up Another Head of Steam; Gains Imminent
March 28, 2024 10:58 AM
View Foot Locker Builds Up Another Head of Steam; Gains Imminent
5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
5 Top-Rated Dividend Stocks With Double-Digit Upside
March 25, 2024 11:19 AM
View 5 Top-Rated Dividend Stocks With Double-Digit Upside
eBay Steadily Climbs as Collectors Drive Growth
March 25, 2024 6:29 AM
View eBay Steadily Climbs as Collectors Drive Growth

All Headlines

Company Descriptions

Addex Therapeutics

OTCMKTS:ADDXF

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Adial Pharmaceuticals

NASDAQ:ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

AzurRx BioPharma

NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

CNS Pharmaceuticals

NASDAQ:CNSP

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Teligent

NASDAQ:TLGT

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial